display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced OC (mOC) - 2nd line (L2)
metastatic/advanced OC (mOC) - 2nd line (L2)
Immune checkpoint association
nivolumab plus ipilimumab NRG GY003

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons